Showing results (111-120 of 172) with videos related to
Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2018
E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced MelanomaAhmad A Tarhini, Sandra J Lee, Xiaoxue Li, et al.Journal for Immunotherapy of Cancer|November 20, 2021
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067Meredith M Regan, Charlene M Mantia, Lillian Werner, et al.Cancer|March 4, 2023
Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patientsZeynep Eroglu, Shifra Krinshpun, Ekaterina Kalashnikova, et al.Cancer|October 11, 2018
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanomaAhmad A Tarhini, Paul Frankel, Christopher Ruel, et al.Medrxiv : the Preprint Server for Health Sciences|July 29, 2024
Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitorsXuefeng Wang, Tingyi Li, Islam Eljilany, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 6, 2024
Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods studyDanielle B Tometich, Carley Geiss, Melinda L Maconi, et al.Frontiers in Immunology|July 13, 2026
iNOS is a key mediator of anti-PD-1 melanoma therapy responseQuang Tam Nguyen, Youngchul Kim, Thi Hong Nga Le, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced MelanomaMeredith M Regan, Lillian Werner, Sumati Rao, et al.Journal for Immunotherapy of Cancer|February 26, 2025
Effector T cells under hypoxia have an altered transcriptome similar to tumor-stressed T cells found in non-responsive melanoma patientsMate Z Nagy, Lourdes B Plaza-Rojas, Justin C Boucher, et al.Journal of Translational Medicine|June 6, 2022
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to malesMariam Saad, Sandra J Lee, Aik Choon Tan, et al.Pageof 18